NCNA on Nasdaq

NuCana plc

NuCana plc is a British pharmaceutical preparations company based in Edinburgh.2 Its shares trade on Nasdaq under the symbol NCNA.2

Price unavailable

Last updated Oct 20, 2026.

Overview

-29.4MNet income, fiscal 20253

Compare with another stock.

  • TickerNCNA on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersEdinburgh, United Kingdom2
  • Incorporated inUnited Kingdom4
  • Business address3 Lochside Way, Edinburgh, X0 Eh12 9Dt4
  • Filer categoryNon-accelerated filer4
  • Legal formPublic Limited Company2
  • LEI213800K5NF92PPHPA3042
  • StatusActive2
  • LEI statusIssued and current2
  • Registered address77 78 CANNON STREET, EC4N 6AF London, United Kingdom2
  • Registered withCompanies House, 033087782

See how the biggest companies compare on our leaderboards

We were incorporated under the laws of England and Wales in 1997 under the name Biomed (UK) Limited, and commenced operations in 2008. On April 28, 2008, we changed our name to NuCana BioMed Limited. On August 29, 2017, we re-registered as a public limited company and changed our name to NuCana plc. On October 2, 2017, we completed our initial public offering of American Depositary Shares, or ADSs, on The Nasdaq Global Select Market. On November 9, 2023 we transferred our listing to The Nasdaq Capital Market. Our ADSs are traded under the symbol “NCNA”.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-120.7%Return on equity3
-$7.5MFree cash flow3

Financial statements

Operating income6789103-$20.1M in 2025+5% since 2018
-$60.0M-$40.0M-$20.0M02018: -$19.1M-$19.1M20182019: -$26.7M-$26.7M2019+40%2020: -$36.4M-$36.4M2020+36%2021: -$47.9M-$47.9M2021+32%2022: -$39.1M-$39.1M2022−18%2023: -$32.8M-$32.8M2023−16%2024: -$22.8M-$22.8M2024−30%2025: -$20.1M-$20.1M2025−12%
Net income6789103-$29.4M in 2025+112% since 2018
-$60.0M-$40.0M-$20.0M02018: -$13.8M-$13.8M20182019: -$21.4M-$21.4M2019+55%2020: -$30.7M-$30.7M2020+43%2021: -$40.5M-$40.5M2021+32%2022: -$32.0M-$32.0M2022−21%2023: -$27.6M-$27.6M2023−14%2024: -$19.0M-$19.0M2024−31%2025: -$29.4M-$29.4M2025+55%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Research and development expenses-12.7M GBP-18.0M GBP-25.1M GBP
Administrative expenses-8.1M GBP-5.0M GBP-6.1M GBP
Impairment of intangible assets0 GBP-33.0K GBP-503.0K GBP
Other income841.0K GBP0 GBP0 GBP
Net foreign exchange gains (losses)-118.0K GBP229.0K GBP-1.2M GBP
Operating loss-20.1M GBP-22.8M GBP-32.8M GBP
Other income1.9M GBP0 GBP0 GBP
Finance income386.0K GBP358.0K GBP754.0K GBP
Finance expense-12.6M GBP0 GBP0 GBP
Loss before tax-30.5M GBP-22.5M GBP-32.0M GBP
Income tax credit1.2M GBP3.5M GBP4.4M GBP
Loss for the year attributable to equity holders of the Company-29.4M GBP-19.0M GBP-27.6M GBP
Basic loss per ordinary share0.00 GBP-0.26 GBP-0.53 GBP
Diluted loss per ordinary share0.00 GBP-0.26 GBP-0.53 GBP

Compare NuCana plc with another company

Corporate structure

NuCana plc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NuCana plc

  • Hugh Griffith Filed SCHEDULE 13D on NuCana plc, latest Mar 18, 2026 (4 filings since Feb 11, 2022)
  • Sofinnova Venture Partners VIII, L.P. Filed SCHEDULE 13D/A on NuCana plc, latest Feb 25, 2025 (3 filings since Feb 28, 2022)
  • SOFINNOVA CAPITAL VI FCPR Filed SCHEDULE 13D/A on NuCana plc, latest Feb 14, 2025
  • BAILLIE GIFFORD & CO Filed SC 13G/A on NuCana plc, latest Oct 4, 2024 (4 filings since Jan 27, 2022)
  • Capital International Investors Filed SC 13G/A on NuCana plc, latest Feb 13, 2023 (2 filings since Feb 11, 2022)
  • Capital Research Global Investors Filed SC 13G/A on NuCana plc, latest Feb 11, 2022
  • NuCana plc Edinburgh, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NuCana plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net658.0K GBP3 Dec 31, 2025197.0K GBP3 Dec 31, 2024+234.0%
Operating-lease assets (leased space)500.0K GBP3 Dec 31, 2025500.0K GBP9 Dec 31, 20220%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents24.3M GBP3 Dec 31, 20256.7M GBP3 Dec 31, 2024+259.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)2.2M GBP3 Dec 31, 20252.2M GBP3 Dec 31, 20240%

Leadership

Who has led NuCana plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Hugh Griffith2026–now

Chief operating officer

  1. Theresa Margaret Bruce Ms.2026–now
Board members and other officers (6)

Former names

  • NuCana BioMed LtdJun 26, 2017 to Aug 4, 20174

Timeline

  1. Mar 18, 2026New chief executive Hugh Griffith becomes CEO12
  2. Jan 28, 1997Founded NuCana plc is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202619

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

144 filings to the SEC since October 2021: 5 annual reports, 12 insider forms, 17 large holders, 110 other. The latest 20:

  1. Sep 30, 20266-K EDGAR
  2. Aug 13, 20266-K EDGAR
  3. Jun 24, 20264 EDGAR
  4. Jun 23, 20264 EDGAR
  5. Jun 8, 20266-K EDGAR
  6. Jun 1, 20266-K EDGAR
  7. May 14, 20266-K EDGAR
  8. May 6, 20266-K EDGAR
  9. Apr 16, 20264 EDGAR
  10. Apr 1, 20263 EDGAR
  11. Mar 24, 20263 EDGAR
  12. Mar 20, 20263 EDGAR
  13. Mar 19, 20263 EDGAR
  14. Mar 19, 2026S-8 EDGAR
  15. Mar 19, 202620-F EDGAR
  16. Mar 19, 20266-K EDGAR
  17. Mar 18, 2026SCHEDULE 13D EDGAR
  18. Mar 18, 20263 EDGAR
  19. Mar 18, 20263 EDGAR
  20. Mar 18, 20263 EDGAR

The 144 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
StoneX Group Inc.47,043$71.5K0.0%New
Citadel Advisors LLC27,099$41.2K0.0%+13,244
Glass Jacobson Investment Advisors llc15,000$22.8K0.0%No change
Rhumbline Advisers4,698$7.1K0.0%+976
Citigroup Inc188$2860.0%New
Integrated Wealth Concepts LLC188$2860.0%New
Hrt Financial LP16,870$250.0%New
Caitong International Asset Management Co., Ltd5$80.0%+3
Morgan Stanley2$30.0%No change
SBI Securities Co., Ltd.1$20.0%New
Acadian Asset Management LLC2$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How NuCana plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNuCana plc1
  • CIK0001709626
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company5
  • Incorporated inEngland and Wales5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3 Lochside Way, Edinburgh, X0 EH12 9DT1
  • Phone44-0-131-357-11111
  • Shares outstanding20,809,854,947 shares as of Dec 31, 20255
  • AuditorErnst & Young LLP, Edinburgh, United Kingdom PCAOB ID 1438; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJun 26, 20171
  • Filings282 in all: 6-K (137), SC 13G/A (30), CORRESP (14), SC 13G (11), UPLOAD (10), 20-F (9), 3 (9), SC 13D/A (9)1
    All 29 form types

    424B5 (7), EFFECT (7), F-1/A (4), 4 (3), F-3 (3), S-8 (3), SC 13D (3), SCHEDULE 13D/A (3), 424B4 (2), CT ORDER (2), DRS (2), DRSLTR (2), F-1 (2), F-6 (2), F-6 POS (2), 8-A12B (1), CERTNAS (1), DRS/A (1), F-3/A (1), F-6/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Mar 19, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing five thousand Ordinary Shares, nominal value £0.0004 per shareNCNAThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 19, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25